A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Moderate to Severe Chronic Non-cancer Pain
Interventions
DRUG

No intervention

This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutica

INDUSTRY